




PHARMACEUTICAL 2020

iBio Inc.
Rank 273 of 358





PHARMACEUTICAL 2020

iBio Inc.
Rank 273 of 358



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 245% points. The greatest weakness of iBio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 174% points.

The company's Economic Capital Ratio, given in the ranking table, is -46%, being 82% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	4,808
Cost of Goods Sold	0
Intangible Assets	1,374
Liabilities, Current	3,458
Liabilities, Non-Current	0
Other Assets	24
Other Compr. Net Income	-1.0
Other Expenses	0
Other Liabilities	24,671
Other Net Income	-1,809
Other Revenues	2,018
Property and Equipment	24,380
Research and Development	5,474
Selling, General and Administrative Expense	12,332

Output Variable	Value in 1000 USD
Assets	30,586
Liabilities	28,129
Expenses	17,806
Revenues	2,018
Stockholders Equity	2,457
Net Income	-17,597
Comprehensive Net Income	-17,598
Economic Capital Ratio	-46%